The examination of sleep disoders in the patients with interstitial lung diseases

The examination of sleep disoders in the patients with interstitial lung diseases - Sleep disoders in the patients with interstitial lung diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028242

Enrollment

125

Registered

2017-12-01

Start date

2017-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

interstitial pneumonia

Interventions

CPAP therapy for the patients with severe sleep apnea syndrome oral appricance therapy for the patients with severe sleep apnea syndrome without treatment for the patients with severe sleep apnea synd

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with interstitial lung diseases who is over 20 years old

Exclusion criteria

Exclusion criteria: patients who have already diagnosed as sleep apnea syndrome

Design outcomes

Primary

Measure	Time frame
prevalence of sleep disorders and severity of QOL score in the patients with interstitial lung diseases at the beginning of the study, changes in QOL score by treating sleep apnea syndrome in the patients with interstitial lung diseases at 3,6,12,24 month after starting the study	—

Secondary

Measure	Time frame
residual apnea-hypopnea index in the patients who took treatment of sleep apnea syndrome, prognosis, frequency of acute exacerbations of interstitial lung diseases at the point of 24 month after starting the study, changes in tricuspid valve regurgitation velocity by echocardiography at the point of 6 month after treatment of sleep apnea syndrome, changes in forced vital capacity and forced vital capacity percent predicted 6,12,24 after treatment	—

Measure

Time frame

residual apnea-hypopnea index in the patients who took treatment of sleep apnea syndrome, prognosis, frequency of acute exacerbations of interstitial lung diseases at the point of 24 month after starting the study, changes in tricuspid valve regurgitation velocity by echocardiography at the point of 6 month after treatment of sleep apnea syndrome, changes in forced vital capacity and forced vital capacity percent predicted 6,12,24 after treatment

—

Countries

Japan

Contacts

Public ContactKazumasa Ogawa

Toranomon Hospital respiratory centor

kaz.sap.tok@toranomon.gr.jp03-3588-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026